The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...